gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE American · IGCHealthcarePharmaceuticals

IGC Pharma, Inc. (IGC)

$0.1950+4.84%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$0.20▼ 49.88% in range
Nov 4, 2025Low $0.18 · High $0.39Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

IGC Pharma closed at $0.20 on Nov 4, up 4.84%, 51.5% below its 52-week closing high. Volume of 325.4K shares was 0.64× its 20-day average (below normal).

Split-adjusted performance: -30.4% over one month, -38.7% over six months, -51.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $265K, down 19.2% from a year earlier, with a net margin of -1107.9%.

Short interest was 635.6K shares at the Oct 15 settlement, down 31.8% from the prior report (0.7% of float, 1.0 days to cover).

Market cap$20.2M103.4M shares
Revenue · quarter$265.0K−19.2% YoY
Diluted EPS$-0.03—
P/E · TTM—
Net margin-1,107.9%Gross 18.1%
Dividend yieldNone
52-week range0.18 – 0.40−51.5% from high
Volume325.4K0.64× 20-day avg
Volatility · 60d63.5%Annualised
Short % of float0.7%1.0 days to cover
Net cash-$728.0KCash $354.0K
Next earnings—Not scheduled
Split-adjusted performance
1W −18.3%1M −30.4%3M −22.0%6M −38.7%YTD −30.7%1Y −51.5%3Y −33.4%5Y −86.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum35
Revenue growth30
Net margin20
Value (low P/E)—
Size21

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short635.6K−31.8% vs prior
Days to cover1.0Settled Oct 15
% of float0.7%
Short vol. 10d28.9%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
IGCIGC Pharma$0.1950+4.84%−38.7%−19.2%−1107.9%—$20.2M
AYTUAYTU BioPharma$1.92−0.52%−25.0%+6.4%−0.1%—$20.9MCompare
COCPCocrystal Pharma$1.01−5.61%−28.4%—−3013.3%—$19.5MCompare
EDSAEdesa Biotech$2.17−4.82%−85.5%———$20.9MCompare
MCRBSeres Therapeutics$2.09+6.63%−73.9%—622.4%—$21.0MCompare
TXMDTherapeuticsMD$1.82+2.25%−10.3%−8.7%17.8%—$21.1MCompare
ATOSAtossa Therapeutics$2.12−9.01%−63.4%———$21.2MCompare
CNTXContext Therapeutics$0.2035+4.90%−91.6%———$18.7MCompare
KTTAPasithea Therapeutics$0.53000.00%−37.6%———$17.7MCompare

News about IGC Pharma

All news →

No recent articles focused on IGC Pharma. 1 articles mention it in passing.

Quick answers

What does IGC Pharma do?
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
What is IGC's market cap?
$20.16M, based on the Nov 4 close of $0.20.
Does IGC Pharma pay a dividend?
No regular cash dividend has been paid in the last year.
How much of IGC is sold short?
635.6K shares, 0.7% of float, as of Oct 15, 2026.
What sector is IGC in?
Healthcare, in the Pharmaceuticals industry.

About IGC Pharma

IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.

HQ: Potomac, MD70 employeesListed Apr 13, 2006igcinc.us

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology